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RESEARCH
Outcomes of stenting after uncomplicated ureteroscopy:
systematic review and meta-analysis
GhulamNabi, clinical lecturer,1 J Cook, statistician,2 J N’Dow, professor of urology,1 SMcClinton, consultant
urological surgeon1
ABSTRACT
Objective To investigate the potential beneficial and
adverse effects of routine ureteric stent placement after
ureteroscopy.
Design Systematic review and meta-analysis of
randomised controlled trials.
Data sources Cochrane controlled trials register (2006
issue 2), Embase, and Medline (1966 to 31 March 2006),
without language restrictions.
Review methodsWe included all randomised controlled
trials that reported various outcomes with or without
stenting after ureteroscopy. Two reviewers independently
extracted data and assessed quality. Meta-analyses used
both fixed and random effects models with dichotomous
data reported as relative risk and continuous data as a
weightedmean difference with 95% confidence intervals.
Results Nine randomised controlled trials (reporting 831
participants) were identified. The incidence of lower
urinary tract symptoms was significantly higher in
participants who had a stent inserted (relative risk 2.25,
95% confidence interval 1.14 to 4.43, for dysuria; 2.00,
1.11 to 3.62, for frequency or urgency) after ureteroscopy.
There was no significant difference in postoperative
requirement for analgesia, urinary tract infections, stone
free rate, and ureteric strictures in the two groups.
Because of marked heterogeneity, formal pooling of data
was not possible for some outcomes such as flank pain. A
pooled analysis showed a reduced likelihood of
unplanned medical visits or admission to hospital in the
group with stents (0.53, 0.17 to 1.60), although this
difference was not significant. None of the trials reported
on health related quality of life. Cost reported in three
randomised controlled trials favoured the group without
stents. The overall quality of trials was poor and reporting
of outcomes inconsistent.
Conclusions Patients with stents after ureteroscopy have
significantly highermorbidity in the form of irritative lower
urinary symptoms with no influence on stone free rate,
rate of urinary tract infection, requirement for analgesia,
or long term ureteric stricture formation. Because of the
marked heterogeneity and poor quality of reporting of the
included trials, the place of stenting in the management
of patients after uncomplicated ureteroscopy remains
unclear.
INTRODUCTION
The surgical management of ureteric stones has chan-
ged over the past few decades because of advances in
instruments and techniques.1 Extracorporeal shock
wave lithotripsy (ESWL) and ureteroscopy are cur-
rently the most common treatment options in clinical
practice. The routine placement of ureteric stents after
fragmentation and retrieval of ureteroscopic stones is
questionable.w1 w2 The main advantages of stenting are
the prevention of ureteric obstruction and renal pain
that may develop as a result of ureteric oedema from
balloon dilation or stonemanipulation during uretero-
scopy.Ureteric stentsmay aid in thepassageof residual
stone fragments secondary to the passive ureteric dila-
tion that occurs with an indwelling ureteric stent2 and
may prevent delayed formation of ureteric stricture.
Routine placement of ureteric stents, however, is
accompanied by recognised potentially troublesome
urinary symptoms or morbidity, or both.3 4 Related
complications such as migration, infection, pyelone-
phritis, breakage, encrustation, and stone formation
are not uncommon.5 Placement of ureteric stents
results in additional costs. Furthermore, unless a pull
string is routinely used at the distal end of the stent,
secondary cystoscopy is required to remove the stent,
which has cost implications and the potential to add to
the disruption of patients’ lives.
Ureteroscopy is now performed with small calibre
endoscopes and better intracorporeal lithotripsy
devices such as holmium laser so that most patients
can be treated without ureteric dilation. As a result,
the need for a postprocedural stent remains question-
able.
We determined the evidence that outcomewith rou-
tine ureteric stent placement after uncomplicated ure-
teroscopy is inferior to that without stent placement.
METHODS
Search strategy
We obtained relevant trials from the Cochrane renal
group’s specialised register of randomised controlled
trials; the Cochrane central register of controlled trials
2006; Medline and PreMedline (1966 to 31 January
2006); Embase (1980 to 31 January 2006); reference
lists of urology textbooks, review articles, and relevant
trials; and abstracts of conference proceedings.
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To be included randomised controlled trials had to
compare stenting with no stenting after uncomplicated
ureteroscopy in adults with a clinical diagnosis of ure-
teric stone who required intervention or who were
undergoing diagnostic or therapeutic ureteroscopy
for upper tract transitional cell carcinoma and had at
least one of the predetermined outcomes of interest.
Outcome measures
Outcomes of interest were pain rated by patients on a
validated scale, need for analgesia, lower urinary tract
symptoms, unplanned medical visits or admission to
hospital, complications related to the stent (such as
migration, encrustation, fragmentation, ureteric ero-
sion, and fistulas), return to normal physical activities,
participants’ satisfaction, health economics and health
related quality of life. Trials reporting on pain were
classified into two groups: those that reported pain
score within or at three days or those that reported
pain at or after day seven after the procedure.
Quality assessment and data abstraction
Two reviewers (GN, SMcC) independently assessed
study quality using the checklist developed for the
Cochrane renal group.6 Discrepancies were resolved
by discussion and arbitration by a third party if neces-
sary. They assessed concealment of allocation, inten-
tion to treat analysis, completeness of follow-up, and
blinding of investigators, participants, and outcome
assessors.
They screened identified titles and abstracts inde-
pendently. Potentially relevant trials were retained
and the full text examined. The reviewers indepen-
dently extracted data. When important data were not
reported, we tried to contact the authors.
Study characteristics and quantitative data synthesis
Whenever possible, we classified the studies by size
and site of stones and type of ureteroscope and intra-
corporeal lithotripsy device used. When two or more
studies reported on the same outcome we quantita-
tively combined results. We calculated relative risks
for dichotomous data and weighted mean differences,
with 95% confidence intervals, for continuous data. A
fixed effects model (Mantel-Haenszel) was used unless
therewas evidence of substantial statistical heterogene-
ity, in which case we used the DerSimonian and Laird
random effects model. Statistical heterogeneity of
treatment effects between studies was formally tested
with Cochran’s test for heterogeneity (P<0.1). The I 2
statistic was also examined.7 We explored possible
sources of heterogeneity (participants, treatments,
study quality).Whenwe could not combine data quan-
titatively they were assessed qualitatively. All meta-
analyses were performed using RevMan software (ver-
sion 4.2.8).
RESULTS
Of 34 potentially relevant studies, we excluded 24 after
reviewing abstracts (fig 1). We retrieved 10 articles for
more detailed evaluation and excluded one that did
not meet our inclusion criteria,8 leaving nine trials for
the review.w1-w9
Study characteristics
The nine trials were conducted in eight countries,
reported on 831 participants, and were published in
2001-4 (table 1). The reported length of hospital stay
after ureteroscopy varied from a few hours as an
outpatientw1 w4 to two to three days.w7 w9 In two trials
hospital stay varied on a case-to-case basis,w3 w6 but ure-
teroscopy was mostly an outpatient procedure with a
few patients requiring overnight hospital stay. Two
trials reported hospital stays of one day.w2 w5 One trial
did not report on postoperative hospital stay.w8
Seven studies included participants irrespective of
the site of stones in the ureterw1 w2 w4-w8 and a few selec-
tively recruited participants with stones in the lower
ureter.w3 w9 There was no significant difference in
stone size between the groups that did or did not
receive a stent. Participants with intraoperative ure-
teric perforation or any other complications that other-
wise would have required postprocedural placement
of a ureteric stent were specifically excluded from the
trials. One trial included participants after diagnostic
or therapeutic ureteroscopy for transitional cell carci-
noma of ureter or pelvicalyceal system.w4
One trial mentioned the material of the ureteric
stents used.w2 Size of stents used varied from 6 French
gaugew2 w3 w4 w6 w9 to 7 French gauge,w5 w7 but two stu-
dies did not specify size.w1 w8 All trials except two
used semirigid or rigid ureteroscopes ranging in size
from 6.0 to 9.5 French gauge. One trial routinely
used a 7.4 French gauge flexible ureteroscope for
upper ureteric stonesw1 while another did so
occasionally.w4 Two studies carried out ureteral dilata-
tion in both groups before the introduction of the
ureteroscope.w3 w9 One study excluded participants
who required dilatation.w4 In three trials ureteral dila-
tation to facilitate ureteroscopy was not
required.w5 w6 w8 Different sources of intracorporeal
lithotripsywere used for fragmentation of large calculi,
including holmium:YAG (yttrium-aluminium-garnet)
laser,w1 w3 w4 w6 electromechanical,w7 w9
electrohydraulic,w5 and ultrasonic lithotrite.w8
Most of the included trials failed to meet our quality
criteria because of lack of information rather than
Potentially relevant trials identified and screened (n=34)
Retrieved for more detailed evaluation (n=10)
Trials excluded: not randomised controlled trial
or no comparison of stents v no stents (n=24)
Trials included in meta-analysis (n=9)
Trials excluded: no randomisation (n=1)
Fig 1 | Flow of studies in the systematic review
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explicit reporting of methods that did not conform to
the criteria. The trial designs were heterogeneous with
regard to ureteroscope sizes, intracorporeal lithotripsy
devices, postoperative analgesia, and outcome assess-
ment and reporting. Only one trial reported on blind-
ing (table 2).
Patients’ outcomes
Patients’ pain scores—Five trials measured pain scores at
variable intervals after the procedure: at day one,w9
days one and three,w6 only at day three,w5 at days
three, seven, and 15,w2 and at one, six, and 12 weeks.
w1 They all used a 10 cm visual analogue scale with 0
representing no pain and 10 representing severe pain.
Experimental studies inminipigs have reported persis-
tent mechanical ureteric oedema and urinary tract
obstruction up to 96 hours after dilatation,9 suggesting
that the cause of flank pain in the first three days after
ureteroscopy is multifactorial and not caused by stents
alone. Two trials reported no significant difference in
pain scores within three days of the procedure between
the groups,w5 w9 whereas one trial favoured those with-
out stents within three days of the procedure.w2 There
was evidence of substantial heterogeneity between stu-
dies for pain scores between both immediate (within or
at three days) and delayed (seven days) postoperative
periods. Because of the large degree of heterogeneity
we could not pool data. One trial reported a signifi-
cantly higher pain score at four weeks in those with
stents,w3 whereas two trials reported no significant dif-
ference at two and 12weeks after the procedure.w1 w2 In
two studies the reported data were not suitable for
inclusion in the meta-analysis,w3 w4 with both trials
reporting a higher pain score in participants with
stents. In one other trial the method of pain measure-
ment was not clear,w7 though it reported no significant
difference in pain perception between groups.
Requirement of analgesia—Four trials reported on the
requirement for analgesia after ureteroscopic removal
of ureteric stones.w1 w6-w8 None of these studies found
any significant difference in the proportion of partici-
pants who required analgesia after ureteroscopy with
or without stents. Only two trials gave data suitable for
meta-analysis.w4 w7 There was no difference in use of
analgesics between the two groups (relative risk 1.03,
95% confidence interval 0.73 to 1.47).
Lower urinary tract symptoms—Eight trials reported on
lower urinary tract symptoms at various lengths of fol-
low-up.w1-w7 w9 Combined analysis of four of these stu-
dies that reported urinary frequency or urgency
showed a higher rate in participants with stents (2.00,
1.11 to 3.62; fig 2). There was also a higher rate of hae-
maturia (2.18, 0.72 to 6.61) and dysuria (2.25, 1.14 to
4.43) in those with stents. Data from three trials, which
could not be used for meta-analysis, also showed
higher rates of lower urinary tract symptoms in those
with stents.w1 w3 w4
Urinary tract infections—Three trials (210 partici-
pants) reported on urinary tract infections.w2 w6 w9 The
pooled analysis showed no significant difference
between the two groups (1.09, 0.48 to 2.47; fig 3).
One trial reported significantly more pyuria in the
initial postoperative period in those with stents. This
Table 1 | Characteristicsof includedstudies comparingstenting (intervention) versusnostenting
(control) after uncomplicated ureteroscopy
Study
Interven-
tion/control
Stone
location Outcomes Notes
Borboroglu w3
USA
53/60 Distal Pain scores preoperatively
and postoperatively at 48
hours and 1 and 4 weeks,
symptoms on 0-100 scale.
Analgesia requirement.
Excretory urography, CT, or
ultrasound at 4 weeks
Day care procedure, except 10
without and 7 with stents.
Ureteroscopes 6.0 to 9.5
French gauge. Multicentre,
stents removed at 3-10 days.
Holmium:Yag laser used for
fragmentation
Byrnew4 USA 38/22 Variable Pain and lower urinary tract
symptoms by questionnaire
on postoperative days 0, 1,
and 6
Semirigidand7.5Frenchgauge
flexible ureteroscope used.
Both holmium laser or
pneumatic lithotripsy used.
Participants with transitional
cell carcinoma of upper tract
included (holmium laser)
Chenw5Taiwan 30/30 Variable Pain on scale of 0-10 before
and after operation, lower
urinary tract symptoms,
unplanned medical visits,
pyuria, KUB radiography and
renograms before and 3, 7,
and 28 days after operation.
Unplanned visits, return to
normal activity
All participants kept overnight,
electrohydraulic energy for
fragmentation. Ureteroscopes
of 6 French gauge
Cheungw6
Hong Kong
29/29 Variable Pain scores on scale of 0-10,
symptoms andUTIs, excretory
urography at 3 months,
renogram if required for
ureteric strictures
Ureteral trauma and oedema
assessed intraoperatively on a
scale of 0-2. Participants with
perforation excluded from
study. Sample size calculated
Damianow2
Italy
52/52 Variable Pain scores on scale of 0-10;
lower urinary tract symptoms
and urinary tract infections,
KUB radiography. Ultrasound
in immediate postoperative
period and at 1 and 3months.
Excretory urography at
6 months
Ureteral trauma and oedema
assessed intraoperatively on
scale of 0-2. All participants
stayed overnight. Antibiotics
used preoperatively and for
5-7 days postoperatively.
Pneumatic lithotripsy for
fragmentation. Ureteroscopes
of 8.9 French gauge
Denstedtw1
Canada
29/29 Variable Pain scores on scale of 0-10;
analgesia requirement, lower
urinary tract symptoms, UTIs
assessed at 1, 6, and
12weeks. KUB radiography at
each postoperative visit and
ultrasound at 3 months
Sample size calculated. 7.5
French gauge flexible
ureteroscopy used for upper
stones. Stents removed at first
visit. Mainly holmium:YAG
laser used for fragmentation
Jeongw7 Korea 23/22 Variable Pain and lower urinary tract
symptoms assessed as mild,
moderate, and severe
depending on duration and
requirement of medications.
UTIs and KUB radiography at 7
and 28 days
Participants admitted to
hospital for 2-3 days,
electromechanical
fragmentation, 7 French gauge
stents used
Nettow8 Brazil 133/162 Variable Pain and postoperative
analgesia requirement, lower
urinary tract symptoms on
modified international
prostatic symptoms score,
plain radiography at
immediate postoperative
period and ultrasound at
2-3 months
Antibioticsusedpreoperatively
and for 5-7 days
postoperatively. Cost of
procedure assessed.
Ultrasound fragmentation.
Ureteroscopes of 7.5 French
gauge
Srivastavaw9
India
26/22 Distal ureter Operative time, postoperative
pain score, analgesic
requirement, symptoms
related tostent, riskofureteral
stricture formation at
3 months
Pneumatic lithotripsy for
fragmentation. Distal ureteric
stones treated. 8.5 semirigid
ureteroscopes used
CT=computed tomography; UTI=urinary tract infection; KUB=kidney, ureter, and bladder.
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resolved, however, and there was no significant differ-
ence between groups by day 28.w5
Unplanned medical visits and admission to hospital—Of
the participants in seven trials, 7% (34/483) required
unplanned medical visits or admission to
hospital.4 w2-w6 w9Most participants weremanaged con-
servatively, except in three trials in which 9/134
patients required another stent.w2-w4 The pooled analy-
sis showed a reduced likelihood of unplanned medical
visits or admissions to hospital in the patients with a
stent (0.53, 0.17 to 1.60; fig 4). One of the studies
reported a significantly higher rate of unplanned
admission in the patients without stents.w2 This was
attributed to the use of a pneumatic intracorporeal
lithotripsy device used for the fragmentation of stones,
which has been shown to leave larger residual frag-
ments compared with the holmium:YAG laser10 used
in other studies. The only other trial that used similar
sources of energy for intracorporeal lithotripsy did not
report a significant difference in the two groups of
participants.w9 Because of the large clinical heterogene-
ity in the use of intracorporeal lithotripsy devices
between trials we could not do a pooled analysis to
assess the effect of energy sources.
Return to physical activity—One trial reported no sig-
nificant difference in the reported return to normal
physical activities between the groups (25 (83%) v 24
(80%) at day one after the procedure).w5
Efficacy outcomes
Ureteric strictures/stone free rate—Of the nine trials, six
reported on the rate of ureteric stricture
formation.w1-w3 w6 w8 w9 There was no difference in the
Table 2 | Assessment of quality criteria for trials reporting on stenting versus no stenting after
ureteroscopic retrieval of stones
Study
Allocation
concealment Intention to treat analysis
Completeness
of follow-up Blinding*
Borborogluw3 Adequate Six participants randomised to group
without stents removed from protocol and
analysis because of intraoperative injury
Reported N/A
Byrnew4 N/A N/A Reported N/A
Chenw5 Adequate N/A Reported N/A
Cheungw6 Inadequate N/A Reported N/A
Damianow2 Adequate N/A Reported N/A
Denstedtw1 Adequate 13 participants excluded from study
because of intraoperative balloon dilatation
Reported N/A
Jeongw7 N/A N/A Reported N/A
Nettow8 N/A N/A Reported Surgeon
Srivastavaw9 Adequate N/A Reported N/A
N/A=not available (insufficient information provided).
*None of the trials provided sufficient information to determine blinding of participants or outcome assessors.
Dysuria
Cheungw6
Srivastava w9
Damiano w2
Jeongw7
Subtotal (95% CI)
Total events: 89 (with stent), 42 (without stent)
Test for heterogeneity: χ2=15.24, df=3, P=0.002, I 2=80.3%
Test for overall effect: z=2.34, P=0.02
Urinary frequency/urgency
Chenw5
Srivastava w9
Damiano w2
Jeongw7
Subtotal (95% CI)
Total events: 86 (with stent), 44 (without stent)
Test for heterogeneity: χ2=11.36, df=3, P=0.01, I 2=73.6%
Test for overall effect: z=2.31, P=0.02
Haematuria
Cheungw6
Damiano w2
Jeongw7
Subtotal (95% CI)
Total events: 49 (with stent), 24 (without stent)
Test for heterogeneity: χ2=9.96, df=2, P=0.007, I 2=79.9%
Test for overall effect: z=1.37, P=0.17
0.1 0.2 0.5 1 2 5 10
Study
23/29
18/26
28/52
20/23
130
25/30
16/26
30/52
15/23
131
16/29
10/52
23/23
104
With stent
(n/N)
2/29
5/22
22/52
13/22
125
4/30
7/22
24/52
9/22
126
1/29
8/52
15/22
103
Without stent
(n/N)
11.69
21.40
33.12
33.79
100.00
17.81
23.58
32.31
26.31
100.00
10.34
32.34
57.32
100.00
Weight
(%)
11.50 (2.98 to 44.37)
3.05 (1.35 to 6.86)
1.27 (0.85 to 1.91)
1.47 (1.00 to 2.16)
2.25 (1.14 to 4.43)
6.25 (2.48 to 15.78)
1.93 (0.98 to 3.83)
1.25 (0.86 to 1.82)
1.59 (0.89 to 2.86)
2.00 (1.11 to 3.62)
16.00 (2.27 to 112.87)
1.25 (0.54 to 2.91)
1.47 (1.10 to 1.95)
2.18 (0.72 to 6.61)
Relative risk
(random) (95% CI)
Relative risk
(random) (95% CI)
Favours
treatment
Favours
control
Fig 2 | Lower urinary tract symptoms in patients with and without stents after ureteroscopy
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proportionof participants developing strictureswithor
without stents. Similarly, none of the trials reported
significant differences in the stone free rates between
participants with or without a stent.
Health related quality of life
None of the trials reported on the quality of life of par-
ticipants.One of the trials assessed participants’ prefer-
ence by asking thosewho received a stentwhether they
would prefer to undergo ureteroscopy without place-
ment of a stent if they needed one in the future.w9
Around two thirds of participants in the stented
group said they would prefer not to have stents after
any future ureteroscopy.
Health economics
Three studies reported on the cost per patient with or
without a stent.w4 w8 w9 Though costs were higher for
the group with stents in all the three trials, the meth-
ods used to estimate costs were not well described
and it is unclear how appropriate any of the costs
estimates were and whether any were transferable
to other settings. In one trial, the reported costs per
patient were based on hospital charges but had been
incorrectly calculated.w8 The operation time (min-
utes), a key cost driver, was consistently longer in
the group with stents (weighted mean difference
5.37, 95% confidence interval 2.37 to 8.36, I 2=0,
fig 5).w1-w6 w9
DISCUSSION
Principal findings
In this systematic review we found that stenting after
ureteroscopy is associated with increased lower urin-
ary tract symptoms such as dysuria and frequency or
urgency. We evaluated the benefits, harms, and costs
of stenting after uncomplicated ureteroscopy, most
commonly for the management of ureteric stones.
Unplanned medical visits and admissions to hospital
were more common in the group without stents,
though the differences were not significant. The clini-
cal implication of these findings needs further research
as the present level of evidence is based on trials with
marked clinical heterogeneity because of the use of dif-
ferent sizes of ureteroscopes, different intracorporeal
lithotripsy devices, and variation in practice and
experience. Moreover, the definition of “uncompli-
cated ureteroscopy” varied between studies. We
could not ascertain whether there was a difference in
postoperative pain because of the small number of stu-
dies reporting on this and the varied results.
We found no significant difference between the
groups with and without stents in the need for postpro-
cedural analgesia, urinary tract infection, stone clear-
ance rates, and ureteric stricture development. These
outcomes, however, were not reported consistently
across the studies. None of the trials reported on health
related quality of life. No trials investigated the impact
of stent design and material on outcome, especially as
related to quality of life. In a randomised study Joshi et
Srivastava w9
Cheungw6
Damiano w2
Total (95% CI)
Total events: 10 (with stent), 9 (without stent)
Test for heterogeneity: χ2=0.32, df=2, P=0.85, I 2=0%
Test for overall effect: z=0.20, P=0.84
Study
1/26
1/29
8/52
107
With stent
(n/N)
0/22
1/29
8/52
103
Without stent
(n/N)
5.66
10.48
83.86
100.00
Weight
(%)
2.56 (0.11 to 59.75)
1.00 (0.07 to 15.24)
1.00 (0.41 to 2.46)
1.09 (0.48 to 2.47)
Relative risk
(random) (95% CI)
Relative risk
(random) (95% CI)
0.2 0.5 10.1 2 5 10
Favours
treatment
Favours
control
Fig 3 | Urinary tract infections proved by culture in patients with and without stents after ureterosopy
Chenw5
Srivastava w9
Borboroglu w3
Damiano w2
Denstedt w1
Byrne w4
Cheungw6
Total (95% CI)
Total events: 9 (with stent), 25 (without stent)
Test for heterogeneity: χ2=9.12, df=6, P=0.17, I 2=34.2%
Test for overall effect: z=1.13, P=0.26
Study
0/30
1/26
0/53
0/52
1/29
1/22
6/29
241
With stent
(n/N)
1/30
0/22
4/54
12/52
1/29
2/28
5/29
244
Without stent
(n/N)
9.62
9.67
11.00
11.57
12.05
14.92
31.17
100.00
Weight
(%)
0.33 (0.01 to 7.87)
2.56 (0.11 to 59.75)
0.11 (0.01 to 2.05)
0.04 (0.00 to 0.66)
1.00 (0.07 to 15.24)
0.64 (0.06 to 6.57)
1.20 (0.41 to 3.50)
0.53 (0.17 to 1.60)
Relative risk
(random) (95% CI)
Relative risk
(random) (95% CI)
0.2 0.5 1 2 5 100.1
Favours
treatment
Favours
control
Fig 4 | Unplanned medical visits or admission to hospital in patients with and without stents after ureteroscopy
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al showednodifference in the impact on patients’ qual-
ity of life between ureteric stents composed of firm or
soft polymer.11 This trial, however, did not have a con-
trol group of participants without stents. In a non-ran-
domised study, up to 80% of participants experienced
urinary symptoms and pain associated with indwelling
ureteric stents, which interfere with daily activities and
result in a reduced quality of life.3 Chen et al reported
return to normal physical activity in 80% of partici-
pants on the day after the procedures in both
groups.w5
A few trials reported on cost implications. Not sur-
prisingly, there was a higher cost associated with use of
ureteric stents, but none of the trials reported on the
cost effectiveness of this intervention.
Limitations
Lack of definition of uncomplicated ureteroscopy—Because
of a lack of standardisation of the definition of “uncom-
plicatedureteroscopy,” the decisionnot to insert a stent
can be difficult. This was evident from the included
trials. This decision is often affected by the technique,
technology used, and experience of the operating sur-
geon. Denstedt et al defined uncomplicated uretero-
scopy as no evidence of perforation or lack of
clinically important oedema.w1 They did not, however,
propose any objective criteria to assess the clinical
importance of any oedema after the procedure but sug-
gested that free flow of contrast into the bladder on
retrograde pyelography should rule it out. Other stu-
dies used an endoscopic, non-validated grading of ure-
teric trauma and oedema on a scale of 0 (mild) to 2
(severe).2 w6
Performance and reporting of studies—There was a lack
of standardisation of outcomemeasures, length of trial,
and duration of stenting. The use of preprocedural
antibiotics, trial design, stent material, patient popula-
tion, assessment of health related quality of life, and
cost-effectiveness data were all inconsistent. Studies
reported pain scores as means with variance, although
it is well recognised that data from visual analogue
scales are often skewed and therefore may be more
accurately analysed as medians. We were unable to
access data from individual patients to assess whether
comparison of medians rather than means may have
altered our findings. Some trials allowed withdrawal
after randomisation because of intraoperative
complications,w2 w3 leading to potential reporting bias.
The longest follow-up was only six months.w2
Quality of reporting—The general quality of trials was
poor (table 2). Some participants were excluded from
the analysis in a few trials because of intraoperative
complications, making it difficult to assess the true
effect of intervention. Most of the trials had small sam-
ple sizes.
Implications for practice
As stent placement after ureteroscopy seems to cause
undesirable lower urinary tract symptoms maybe it
should not be a standard practice. There are, however,
many unanswered questions, and any recommenda-
tions would be potentially flawed because of a lack of
standardisation of outcome measures, marked clinical
heterogeneity, withdrawal after randomisation, impre-
cision in measurement of outcomes (large confidence
intervals), and poor reporting of published clinical
trials.
Implications for research
Research efforts shouldnowbe concentratedonhigher
quality, more rigorous randomised trials. As a mini-
mum, these should use predefined ideally standardised
measures of outcome and be multicentred to ensure
that the studies give sufficiently precise estimate of
the various outcomes. Trials should be protocol driven
and a detailed protocol of how the project is to be con-
ducted should be agreed before the start. The protocol
should state the research objectives, reasons for the
study, issues related to recruitment (inclusion and
exclusion criteria), information to be collected at
entry to the study, and interventions of interest, and
there should be an agreed follow-up protocol. Out-
come measures must include outcomes assessed by
patients and ideally health economic outcome mea-
sures. The impact of variations in stent design, size,
and material, and the effect of different types of intra-
corporeal lithotripsy sources on the requirement for
stents need to be examined.
This review was conducted with substantial support and advice from the
members of Cochrane Incontinence Group, Aberdeen. The health services
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Fig 5 | Operation time (minutes) in patients with and without stents during ureteroscopy
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WHAT IS ALREADY KNOWN ON THIS TOPIC
Stenting after ureteroscopy may lead to undesirable lower urinary tract symptoms with
limited benefits to patients
WHAT THIS STUDY ADDS
Stent placement after ureteroscopy results in considerable morbidity in the form of irritative
lower urinary tract symptoms
It does not seem to influence stone free rate, rate of urinary tract infection, requirement for
analgesia, or long term ureteric stricture formation
The role of stenting in uncomplicated ureteroscopy remains unclear
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